St. Louis Trust Co held its position in Pfizer, Inc. (NYSE:PFE) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 12,862 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. St. Louis Trust Co’s holdings in Pfizer were worth $432,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Altfest L J & Co. Inc. boosted its position in Pfizer by 67.0% in the 2nd quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock valued at $3,603,000 after buying an additional 43,024 shares during the last quarter. Sphera Funds Management LTD. bought a new position in Pfizer in the 1st quarter valued at $13,342,000. Searle & CO. boosted its position in Pfizer by 92.7% in the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock valued at $2,739,000 after buying an additional 38,500 shares during the last quarter. Cadence Bank NA boosted its position in Pfizer by 1.4% in the 2nd quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock valued at $3,358,000 after buying an additional 1,428 shares during the last quarter. Finally, Insight 2811 Inc. boosted its position in Pfizer by 3.7% in the 1st quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock valued at $319,000 after buying an additional 329 shares during the last quarter. Institutional investors and hedge funds own 69.01% of the company’s stock.
Shares of Pfizer, Inc. (NYSE:PFE) opened at 35.60 on Monday. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $36.78. The company’s 50-day moving average price is $35.81 and its 200 day moving average price is $33.90. The firm has a market cap of $211.73 billion, a P/E ratio of 26.04 and a beta of 1.00.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.64 earnings per share. On average, equities analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.60%. Pfizer’s dividend payout ratio (DPR) is currently 94.12%.
PFE has been the topic of a number of recent research reports. Cowen and Company set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Monday, August 14th. Jefferies Group LLC set a $35.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Thursday, August 24th. Berenberg Bank reiterated a “hold” rating and issued a $36.00 price objective (down from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. Deutsche Bank AG set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Finally, Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $38.32.
COPYRIGHT VIOLATION WARNING: This report was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.com-unik.info/2017/10/30/st-louis-trust-co-continues-to-hold-stake-in-pfizer-inc-pfe.html.
In other news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the transaction, the insider now owns 145,649 shares in the company, valued at $5,097,715. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock worth $15,813,961 in the last ninety days. Insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.